🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📣 PAPER ALERT 🚨 Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer's disease 🧵 (1/7) medrxiv.org/content/10.110…

Very nicely written article for the lay public. Discusses importance of starting DM therapies early. washingtonpost.com/wellness/2024/…

Interesting progress in the diagnosis of PD and other synucleinopathies. alzforum.org/news/research-…

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do! 🔗Click the link below to read the interview: acumenpharm.com/ask-acumen/ #AskAcumen #EmployeeSpotlight

Today we launched our new BioFINDER website! It describes our six ongoing BioFINDER studies in detail. biofinder.se

Great Alzforum summary of donanemab ad comm meeting. alzforum.org/news/community…

APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease Yakeel T. Quiroz, PhD (she/her); I vividly remember you presenting this at our Atypical Alzheimer's Disease PIA symposium at AAIC. Great to see it published NEJM, congrats!!! Background: In a person with autosomal dominant Alzheimer’s disease

Blood Proteins May Foretell Parkinson’s Disease Up to Seven Years Prior | ALZFORUM alzforum.org/news/research-…

The #CTAD24 preliminary program is now online! Check out our Oral Communications on Tuesday, October 29! 👇 ctad-alzheimer.com/program-0

FDA approves treatment for adults with Alzheimer’s disease | FDA fda.gov/drugs/news-eve…

Researchers have announced the release of a massive dataset from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) and LEARN study – the first and largest clinical trial of pre-symptomatic Alzheimer's disease. atrinews.usc.edu/landmark-alzhe…

Excellent discussion of rapid advancements in AD blood tests. alzforum.org/news/conferenc…

Today’s The Telegraph first to report MHRA approval of #Leqembi - the first drug to show slowing decline of #Alzheimers. Not a wonder drug but the beginning of us having treatments that change the course of disease.

A Country Doctor, But Oh So Much More: Francisco Lopera, 73 | ALZFORUM alzforum.org/news/community…

FDA Approves New IV Maintenance Dosing for Alzheimer Treatment Lecanemab neurologylive.com/view/fda-appro…

On behalf of all of my co-authors, I am sharing a collective response to the book "Doctored" by Charles Piller and in response to his NYT article promoting the book. Liana Apostolova, MD, MSc, FAAN Lea T. Grinberg, M.D, Ph.D David Holtzman Lamb Lab Cynthia Lemere @MaluTansey Eric Siemers et al. Full author list shown.

Federal Register Blackout Blocks NIH Funding | MedPage Today medpagetoday.com/special-report…

Elected not to cancel this X account but look for me on BS eric siemers. Enough is enough.

Important article for the field available in open access: Donanemab: Appropriate use recommendations. G.D. Rabinovici et al. sciencedirect.com/science/articl… #Donanemab jpreventionalzheimer

Our 2025 Alzheimer’s Disease Facts and Figures is a call to action – to do more, to make more progress, and to give people more reasons to believe that our vision of a world without Alzheimer’s and all other dementia is possible.